All Insights Report Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

    Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

    Real-World Evidence

    Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

    A Patient-Level Simulation Study

    Download Report
    Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

    Chauhan A, Samnaliev M, Ken-Opurum J, Sai Srinivas S, Mehta AM, Dex T, Charland S, Revel A, Preblick R

    About 37.3 million people in the US have Type 2 Diabetes Mellitus (T2DM), accounting for more than 95% of all diabetes cases. The objective of this study was to identify two real-world cohorts of individuals with T2DM from an integrated claims and EHR database who meet the criteria for treatment with iGlarLixi and apply a Monte Carlo simulation to mirror the treatment arms in the LixiLan-O and LixiLan-L trials, thus evaluating the clinical benefits of iGlarLixi in these patients.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Treating Patients With Type 2 Diabetes Mellitus

    Blog

    RWE in Clinical Trials – Market Trends and Use Cases

    Treating Patients With Type 2 Diabetes Mellitus

    Report

    Risk Of Venous Thromboembolism And Major Bleeding In Patients With Acute Medical Illness Receiving Thromboprophylaxis With Enoxaparin

    Treating Patients With Type 2 Diabetes Mellitus

    White Paper

    Real-World Data-Based Simulations: Generating Medical Evidence From Clinical Trial And Real-World Data